Q-omics provides the consensus-scored TAAR6 profile across patient tissues and cancer cell-line models. TAAR6 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TAAR6 is differentially expressed in 2, with the highest sampling consensus in KICH. Additionally, TAAR6 RNA expression shows 6,659 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, KICH, and TGCT as cancer lineages where TAAR6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAAR6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAAR6 survival associations across molecular data types. TAAR6 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAAR6 RNA expression–survival associations across cancer types. High TAAR6 expression shows unfavorable associations in LIHC, UVM, LUSC and ACC, but favorable associations in KIRC and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LIHC as the clearest survival context for TAAR6 RNA expression.
This table summarizes TAAR6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TAAR6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAAR6 shows lower tumor expression in KICH and higher tumor expression in LUAD. The KICH box plot shows higher TAAR6 RNA expression in normal versus tumor tissue (log2 FC = −0.123, t-test p < 0.001).
This table shows molecular features associated with TAAR6 in patient tissues and cancer cell lines. In patient samples, TAAR6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TAAR6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
